news
Turning AI into a biological design engine
DenovAI has unveiled a powerful AI-driven protein design platform capable of creating new, functional synthetic proteins from scratch - marking a big step forward for drug discovery.
List view / Grid view
Pfizer
news
Pfizer to acquire ReViral and its respiratory syncytial virus therapeutic candidates
Pfizer has announced its acquisition of ReViral to advance disease research and development with a complementary strategy to help improve patient outcomes through treatment for respiratory syncytial virus infections and prevent illness through vaccination.
article
Treating cancer patients with cancer anorexia-cachexia syndrome
In this article, Patrick Kendall, Scientific Advisor for Artelo Biosciences, outlines why future treatment of cancer anorexia-cachexia syndrome may lie with drugs in development offering a mechanistic approach.
news
Antibodies that can neutralise SARS-CoV-2 Omicron variant identified
A study has revealed four classes of antibodies that can neutralise Omicron by targeting one of four areas of the spike protein present in SARS-CoV-2 variants.
article
Protecting liposomes in COVID-19 mRNA vaccines could increase their stability
A team from the University of Texas at Dallas has shown that a novel buffer solution is effective at stabilising the liposomes and lipid nanoparticles in certain COVID-19 vaccines.
news
UK Government launches Pandemic Preparedness Partnership group
The UK has launched the Pandemic Preparedness Partnership which will advise the G7 Presidency how to reduce vaccine development time from 300 to 100 days.
article
Neuropilin-1: a key receptor in SARS-CoV-2 infection
Results of a recent study by researchers at the University of Bristol indicate neuropilin-1 is an important host factor for SARS-CoV-2 infection. The team suggests that blocking neuropilin-1 may be a valuable therapeutic intervention in the treatment of COVID-19. Nikki Withers spoke to one of the study’s lead investigators, Dr…
article
Treating cytokine storms in COVID-19 patients
Enosi Life Science researchers Sir Marc Feldmann, Dr H Michael Shepard and Dr Fiona McCann explain why anti-TNF therapies may be effective in treating COVID-19 associated cytokine storms and other inflammatory conditions.
news
Novel antiviral drug candidate blocks SARS-CoV-2 reproduction in cells
In human cells, a drug candidate called PF-00835231 has demonstrated success at blocking the reproduction of SARS-CoV-2.
article
COVID-19 and big pharma: what are 15 leading companies doing to develop a coronavirus vaccine?
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
article
Transitioning novel peptide hits into lead compounds
Unlike synthetic compound libraries, natural product hits must be identified and characterised, as the molecule is often unknown. Venom peptides are often inherently stable due to cysteine knots whereas other peptides may not be. Steve and Carol Trim discuss the challenges of the hit-to-lead journey with these non-standard hits.
article
Open innovation – a collaboration between academia and the pharmaceutical industry to further leverage drug discovery expertise and assets
Increasing numbers of companies in the pharma industry are consolidating their services and outsourcing to CROs to reduce business costs. AstraZeneca’s Marian Preston, David Murray and Mark Wigglesworth discuss how this can not only drive innovation but also prove successful in identifying lead compounds, as evidenced through recent collaborations.
news
Immune system found to protect against MRSA infections
Researchers have discovered how the immune system might protect a person from recurrent bacterial skin infections caused by Staphylococcus aureus...
news
NRF2 pathway provides new approach to cancer drug discovery
Scientists have developed a promising new strategy for the discovery of novel anti-cancer therapies for non-small-cell lung cancers...
webinar
Skin toxicity mechanisms associated with mGluR5 negative allosteric modulators
11 August 2017 | By DiscoverX
In this webinar, DiscoverX Corporation discuss three negative allosteric modulators of metabotropic glutamate receptors, developed by Pfizer, which recently failed in preclinical development due to delayed type IV skin hypersensitivity observed in non-human primates...
